Abstract Purpose of Review Immune checkpoint inhibitors (ICIs) have become a mainstay of
oncologic treatment over the past decade. There are currently 11 ICIs approved by the US …

Cutaneous toxicities frequently occurred with immune checkpoint inhibitors (ICIs), although
clinical and pharmacological features are incompletely characterized. The US Food and …

Immune checkpoint inhibitors (ICPi) have emerged as a new frontier of cancer therapy.
Although monoclonal antibodies to cytotoxic T-lymphocyte associated protein 4 (CTLA-4) …

Immune checkpoint inhibitors have proven to be efficacious for a broad spectrum of solid
organ malignancies. These monoclonal antibodies lead to cytotoxic T-cell activation and …

Abstract Purpose of Review Immune checkpoint inhibitor (ICI) therapy has changed the
landscape of cancer treatment and now represents part of the treatment regimen for …

Abstract Background/Objectives The immune checkpoint inhibitors (ICIs) have been
increasingly associated with severe cutaneous adverse reactions (SCARs). These reactions …

Immune checkpoint inhibitors (ICIs) represent a major breakthrough in cancer therapy.
Immune-related adverse events (irAEs) may occur during treatment due to their unique …

Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment. The unique
spectrum of immune‐related adverse events (IrAEs) may occur during treatment …

The introduction of immune checkpoint inhibitors (ICIs) has transformed the management of
various malignancies. Alongside their therapeutic success, the widespread application of …

Immune checkpoint inhibitors (ICIs) are increasingly used in cancer therapy and can have
unintended side effects affecting several organ systems. Immune-related cutaneous adverse …